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 SYNOPSIS 23 
Background: Benznidazole is one of the two most effective antiparasitic drugs for 24 Chagas Disease treatment. However, the knowledge about its toxicity profile is 25 mostly based on post-marketing observational studies. 26 
 27 
Objectives: Our study combines data from two prospective clinical trials designed 28 to control safety for the drug newly produced by ELEA Laboratories (Abarax®).   29  30 
Methods: Eligible participants were selected by consecutive sampling strategy in 31 CINEBENZ and BIOMARCHA study between 2013 and 2016 (EUDRACT 2011-32 002900-34, 2012-002645-38; and clinicaltrials.gov NCT01755403, NCT01755377, 33 respectively). Enrolled subjects received treatment with benznidazole 34 5mg/kg/day orally in two divided doses for eight weeks and were followed-up 35 fortnightly.  36  37 
Results: We observed 305 adverse reactions among 85 out of 99 participants 38 (85.9%). Each patient had a median of three adverse reactions, 89.5% were mild 39 and the median duration was 12 days. Most adverse reactions appeared in the first 40 month of treatment except arthritis and peripheral neuropathy. 26 patients did not 41 complete treatment: two were withdrawn, one for ectopic pregnancy and one for 42 epilepsy relapse due to cysticercosis; two were lost to follow-up and 22 due to 43 adverse reactions, two of them severe. We observed some unexpected adverse 44 reactions that have not been described previously such as psychiatric symptoms, 45 erectile dysfunction, menstrual cycle alterations or lung infiltration.  46  47 
 Conclusions: There is a very high frequency of adverse reactions to benznidazole. 48 Most adverse reactions are mild but the treatment burden is significant and 49 unexpected reactions are not rare. Severe reactions are uncommon but they can be 50 life threatening. Further studies are necessary to optimise treatment. 51 
 52 53 
 INTRODUCTION 54 Chagas Disease is a chronic anthropo-zoonotic disease caused by the protozoan 55 
Trypanosoma cruzi and it is most frequently transmitted through a vectorial route. 56 However, it is also a major public health problem in endemic and non-endemic 57 countries given its transmissibility from mother to child or through blood products 58 and organ transplants. Outbreaks with oral transmission have been also 59 described.1-3 It is estimated that 6-7 million people could be infected worldwide 60 and 20-30% of them could develop a potentially life-threating cardiac condition.1  61  62 The treatment in acute cases is very effective whereas in chronic disease the 63 effectiveness has been highly debated.4-6 There is a general understanding that 64 parasitic persistence increases the risk of cardiac lesions in chronically infected 65 patients and therefore parasite eradication may be necessary in the early stages of 66 the disease.7 On the other hand, the advanced cardiac stage is irreversible and 67 treatment of this stage is futile. The BENEFIT trial supported this concept 68 considering that it did not show significant morbidity or mortality reduction with 69 antiparasitic treatment in advanced cardiac stage.5,8-9 However, this study did not 70 provide answers about the long-term effectiveness of the antiparasitic approach in 71 early stages of the chronic disease. In the latest years the evidence from 72 observational studies has supported treating most of the chronic patients with the 73 available antiparasitic drugs.10-11  74  75 At the moment, the most effective drugs to treat Chagas disease are benznidazole 76 and nifurtimox. Both drugs have shown poor tolerance, significant adverse 77 reactions (ARs) and high treatment suspension rates. They were registered and 78 
 used in clinical practice since their launch in the 1970s with little understanding of 79 their mechanism of action and toxicity. Early comprehensive preclinical 80 toxicological investigation were conducted for nifurtimox whereas no equivalent 81 information has been available for benznidazole.12 Given that no pre-marketing 82 safety studies were performed for, most of the available knowledge on human 83 safety has been built up based on post-marketing retrospective observational 84 studies. Very few studies have been designed to offer a systematic post-marketing 85 surveillance, which could explain the variability in side effect reports between 86 different groups in addition to race or genetics differences.  87  88 Expert’s forums have discussed about the possibility of different safety profiles 89 depending on the drug manufacturer. This question was raised mostly when Elea 90 laboratories took responsibility of producing after a dramatic period of 2 years of 91 lack of benznidazole stock worldwide between 2011 and 2013.13 There were some 92 concerns that the drug produced by the Brazilian state-owned laboratory LAFEPE 93 and Elea Laboratories from Argentina may have a different toxicity profile, even if 94 some retrospective studies did not observe any significant differences in treatment 95 withdrawals.14  96  97 The aim of this study is to offer a systematic evaluation of safety in a prospective 98 study about the drug manufactured by Elea Laboratories in chronically infected 99 adults.  100  101 102 
 PATIENTS AND METHODS 103 
Study design 104 From 2013 to 2016 we conducted two prospective, open-label and single centre 105 clinical trials in the International Health Department at Hospital Clinic of 106 Barcelona. CINEBENZ was designed to study the population pharmacokinetics of 107 benznidazole and BIOMARCHA monitored cardiac biomarkers before and after 108 treatment (EUDRACT 2011-002900-34 and 2012-002645-38, and clinicaltrials.gov 109 NCT01755403 and NCT01755377 registration numbers respectively). The 110 protocols were approved by the Ethics Committee of the Hospital Clinic of 111 Barcelona and AEMPS (the Spanish Agency of Medicines and Medical Devices), 112 they were conducted in accordance with the Declaration of Helsinki and national 113 and institutional standards. Before inclusion in the study, all patients provided 114 written informed consent. Both studies had the same treatment and follow-up 115 protocol during treatment and the ARs of both studies were analysed together.  116  117 Eligible subjects met the inclusion criteria of being at least 18 years old, diagnosed 118 by two different positive Trypanosoma cruzi serologic tests, not to have received 119 treatment before and not to have advanced cardiac disease. Exclusion criteria were 120 hypersensitivity to benznidazole, difficulties to follow-up, immunodeficiency, 121 hepatic or renal impairment, cardiac disease of other origin, pregnancy or 122 lactation. Enrolled subject received treatment with benznidazole 5 mg/kg/day 123 orally with or without food in two divided doses for eight weeks, with a maximum 124 of 400mg/day (Abarax®, Elea Laboratory, Argentina).  125  126 We selected all subjects attending health facilities meeting the inclusion and 127 
 exclusion criteria with consecutive sampling strategy. Patients were followed-up 128 fortnightly with clinical review and blood test. The clinical review consisted of an 129 open interview plus an exhaustive structured questioning, a physical examination 130 and vital sign measurements. Patients had a contact telephone number available 131 24h and they could be seen ad-hoc in the clinic if needed. As per site protocol at the 132 time, no food restriction was applied but commitment to avoid alcohol during 133 treatment was required.  134   135 
Data management and Statistical analysis  136 Data collection and management were performed using OpenClinica open source 137 software, version 2.0.3.1. (Copyright© OpenClinica LLC and collaborators, 138 Waltham, MA, USA, www.OpenClinica.com). Data were described using frequencies 139 for discrete variables and median (IQR) for continuous variables. ARs incidence 140 rates and confidence intervals based on Poisson distribution were estimated. 141 Multilevel Poisson regression models were employed to assess fortnightly 142 incidence rate ratio (IRR) of ARs.15 To assess the existence of a time trend of the 143 IRR of ARs, the same models were performed using day instead of fortnight. 144 Following clinical criteria, all models were adjusted by sex and age. The 145 significance level was set at 0.05. The analysis was carried out using Stata 146 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 147 StataCorp LP).  148  149   150 
 RESULTS 151 Out of 100 eligible patients, 99 received treatment with BNZ and one patient 152 declined to participate. Baseline demographic and clinical characteristics can be 153 seen in Table 1. In the cohort, 97 patients (98.0%) were Bolivian, 73.7% were 154 women and the median age was 36 (IQR 9). Regarding to Chagas Disease form, six 155 had a mild heart disease and the rest did not have any evidence of organic disease. 156 Out of 99 participants, 26 patients (26.3%) did not complete treatment: 22 due to 157 ARs; two were lost to follow-up; two had withdrawals criteria with severe 158 consequences, one for pregnancy and one for epilepsy relapse.  (Table 2) 159  160 Eighty-five patients out of 99 (85.9%) had 305 ARs. Among patients with ARs each 161 patient had a median of 3 ARs (IQR 1). Following WHO Toxicity Grade scale, the 162 majority of ARs were mild (n=273, 89.5%), 30 were moderate (9.8%) and two 163 were severe (0.7%). The median time to onset to the first AR was nine days (IQR 164 12) and the majority of the ARs (81.8%) appeared in the first month of treatment. 165 (Figure 1) The median duration of all ARs was 12 days (IQR 9.5). 136 (44.6%) of 166 the ARs required some intervention or medication whereas the rest resolved with 167 no medical treatment. Among the 85 patients who had ARs, the majority had 168 dermatological (74%) or neuropsychiatric symptoms (60%), followed by digestive 169 (40%), general (32%), musculoskeletal (21%) and reproductive system disorders 170 (5%), and only one patient had pulmonary symptoms. (Table 3) 171  172 The ARs leading to suspend treatment were: rash (n=7), arthritis (n=3), peripheral 173 neuropathy (n=3), anxiety (n=3), fever (n=2), general malaise (n=1), angioedema 174 and pulmonary symptoms (n=1), drug rash with eosinophilia and systemic 175 
 symptoms (DRESS) syndrome (n=1) and treatment intolerance in context of 176 consumption of high dose of alcohol (n=1). Among them, four patients decided to 177 stop treatment before medical advice and three other patients suspended 178 treatment because they were unable to return to the clinic for follow-up. By site 179 protocol, we suspended treatment to patients reporting fever, peripheral 180 neuropathy (including ageusia) and arthritis. The rest of patients who did not 181 complete treatment had unexpected or severe ARs. (Table 2)  182  183 Among patients who did not complete treatment the median duration of treatment 184 was 25.5 days (IQR 27) (Figure 2) and the median cumulative dose of benznidazole 185 at the end of treatment 7450.0mg (IQR 9400.0). Among patients who completed 186 treatment the median duration of treatment was 57 days (IQR 6) and the median 187 cumulative dose at the end of treatment 18350.0mg (IQR 5950.0). 188  189 Ten unexpected ARs were recognised during treatment. Four cases of psychiatric 190 symptoms were observed, one severe, two moderate and one mild. The cases 191 involved sleeping disorders, anxiety and panic attacks and in the most severe cases 192 tremor and persecutory delusions. One case had history of anxiety and one patient 193 had personal difficulties during treatment. No other explanation was found in two 194 other cases. There were two cases of amenorrhea during treatment. One woman 195 missed only one cycle whereas the other missed three cycles. Pregnancy test were 196 negative, there was no history of irregular menstrual periods and no other reason 197 was found. Two men reported erectile dysfunction during treatment after 8 and 36 198 days of treatment.  The dose until onset was 2200mg and 11850mg and symptoms 199 lasted between 100 and 148 days. Only one patient recognised personal issues at 200 
 the time and no vascular or hormonal disorders were found. Finally, one patient 201 presented with bronchospasm, basal lung infiltrations in the chest X-ray and basal 202 tree in bud nodules in the CT scan with no other explanation after the study. (Table 203 2) 204  205 We had blood test data of 98 out of 99 patients during treatment and 61 patients 206 (62.2%) had blood test alterations. The majority of blood test disorders were mild 207 and none of them leaded to treatment suspension by itself. Two cases with 208 moderate increase of transaminases could not be contacted to stop treatment and 209 by the next appointment liver tests were back to normal. All the severe blood 210 results were related to the DRESS syndrome and treatment was suspended for 211 clinical reasons before blood test were acknowledged. (Table 4) The median time 212 to onset to present with alterations in liver function tests was 28.5 days (IQR 35) 213 whereas white blood cell disturbances appeared earlier with a median time to 214 onset of 14 days (IQR 14). 215  216 The overall AR incidence rate was 9.2 ARs (95%CI 8.2-10.3) per ten person-217 fortnights. The incidence rate for mild ARs per ten person-fortnights was 8.2 218 (95%CI 7.3-9.3), 0.9 for moderate ARs (95%CI 0.6-1.3) and 0.1 for severe ARs 219 (95%CI 0-0.2). Dermatological and neuropsychiatric reactions had the highest 220 incidence rate among different AR types. (Table 5) 221 
  222 A Multilevel Poisson Regression analysis adjusted by age and sex showed strong 223 evidence that the overall incidence rate was much higher in the first fortnight with 224 a decreasing trend in the following fortnights. This pattern was similar in all 225 
 different categories of ARs except for musculoskeletal ARs where there was no 226 evidence of different incidence rates among the four fortnights (p=0.3005). (Table 227 5)  228  229 There are two types of ARs that tend to appear later during treatment: arthritis 230 and peripheral neuropathy. We observed 11 cases of possible peripheral 231 neuropathy. Four of them were subtle and non-typical: bitter taste (n=1), 232 temporary burning feeling in hands and feet (n=1) and intermittent dysesthesia in 233 hands (n=2). The time to onset in these cases varied between 5-32 days and no 234 treatment suspension was medically advised. The other seven cases had 235 established peripheral neuropathy, two with ageusia and five with peripheral 236 numbness or neuropathic pain. The median time to onset in these cases was 46 237 days (IQR 13) and the median dose to onset 15350mg (IQR 4550). All cases on 238 treatment were advised to discontinue treatment. The median symptoms duration 239 was 31 days (IQR 48). One patient had an electromyoneurography where small 240 fibre polyneuropathy was observed and symptoms lasted 321 days. Arthritis was 241 observed in six cases: two monoarthritis, two polyarthritis, one migratory and one 242 additive case. Large joints such as knees or shoulders were affected in all cases. 243 The patients with polyarthritis and migratory arthritis also presented with wrist, 244 hip and ankle involvement and the migratory arthritis case was the only one where 245 metacarpophalangeal joints were affected. All cases of arthritis appeared after at 246 least 31 days of treatment (median 33, IQR 23), with the median of cumulative 247 dose of 9300mg (IQR 5750) and all cases were women.  248  249 
 Finally, there was some evidence that women may have higher incidence of ARs 250 compared to men when adjusted by age (p=0.0164). Overall, taking into account all 251 ARs, women had 53% higher incidence of ARs than men (95%CI 1.08-2.17). 252 
 253 254 
 DISCUSSION 255 The results of this study are in agreement with most previous observational 256 studies showing poor tolerance to benznidazole.14,16-20 With the most widely used 257 dosage of 5mg/kg/day for 60 days there is a high frequency of ARs with an 258 important disease burden for patients. Only 14 % of patients were free of ARs 259 whereas the majority had several consecutive or simultaneous ARs and suffered 260 for each of them the median of 12 days. Most ARs were mild but significant ARs 261 appeared up to 10% of the cases. Skin reactions, neuropsychiatric ARs (including 262 headache) and digestive symptoms were consecutively the most frequent ARs 263 involving 82% of all ARs.  264  265 The most severe ARs presented in this study have been already described in 266 literature. Eight cases of DRESS syndrome, two of them overlapped with Stevens-267 Johnson syndrome and toxic epidermal necrolysis; another case of Stevens-268 Johnson syndrome and two cases of acute generalised exanthematous pustulosis 269 have been reported.14,18-19,21-22 Thus, life-threatening skin ARs, even uncommon, 270 are not rare and underlines the need of close benznidazole treatment monitoring. 271 In our cohort angioedema appeared in 3% of exposed with the only severe case 272 being the patient with DRESS syndrome. Molina et al observed angioedema in 273 1.1% of their patients whereas Miller et al. described it up to 20% of their 274 cohort.14,16 Patients in this latter study were mostly from Northern and Central 275 America and different ethnicity or Trypanosoma genotype may explain the 276 difference in ARs prevalence.19  277  278 
 Eighty per cent out of the patients with ARs had their first AR in the first 30 days of 279 treatment, which supports the theory that most ARs are secondary to 280 hypersensitivity reactions.19 However, it is consistent in all studies that some 281 cumulative dose or treatment duration is necessary for arthritis and peripheral 282 neuropathy to appear. In the previous arthritis series published by our group 283 arthritis symptoms appeared at least after 40 days of treatment and a cumulative 284 dose of 7500mg.23. In the current study all cases of arthritis appeared after at least 285 31 days of treatment and a cumulative dose of 7250mg, and typical peripheral 286 neuropathy after at least 22 days of treatment and a cumulative dose of 5850mg. 287 These results support the theory that arthritis and peripheral neuropathy may be 288 secondary to toxicity produced by BNZ and therefore 30 days of treatment would 289 prevent most of the cases.24 However, data from this study do not support the 290 threshold of 18g described in some other studies as a threshold for toxicity driven 291 ARs.25 Our results do not agree either with previous study results were bone 292 marrow depression appeared late in treatment as white blood cell disturbances 293 were observed with a median time to onset of 14 days.24  294  295 We have observed some unexpected ARs that have not been described in previous 296 studies. Even if sleeping disorders, either insomnia or sleepiness, have been 297 already reported in some cohorts, it is the first time in our knowledge that 298 psychiatric symptoms such as anxiety, panic attacks, emotional lability or 299 persecutory delusions have been described. 14,16,18 These results may suggest some 300 central nervous system effect by BNZ. Some patients also presented with erectile 301 dysfunction or delay in menstrual cycle with no other good explanation for these 302 symptoms. One patient had bronchospasm and bibasal lung infiltration that 303 
 disappeared after treatment suspension and could not be explained with her 304 medical history. All ARs had no permanent consequences except one case of 305 erythema dyschromicum perstans in both legs diagnosed by histopathology six 306 months after having a moderate skin rash reaction. Finally, we suspended 307 treatment in a patient with an ectopic pregnancy during treatment. She had other 308 risk factors such as a long history of infertility and exposition to two days of 309 Mequitazine. Mequitazine has not demonstrated any teratogen effect in animal 310 studies but information in humans is insufficient to ensure safety in pregnancy. On 311 the other hand, some studies in pregnant rats observed that BNZ could cross the 312 placental barrier and reach the foetuses.12 The association between the ARs and 313 BNZ could not be ruled out in all those cases. Future pharmacovigilance data will 314 be needed to conclude if there is any real association. 315  316 Treatment suspension rate was 26% in our study with free and flexible health care 317 access. However, six patients presented difficulties to have a safe social 318 environment to endure with the treatment: three patients had difficulties to attend 319 to clinical review due to work-related limitations and three other patients could 320 not cope and felt ashamed because of stigmatising skin reactions in an already 321 vulnerable population. These results manifest how social support has an impact in 322 treatment’s effectiveness and migrants are exposed to health care access 323 limitations attributable to the lack of social support.26-27  324  325 Our study may have a generalisability limitation given almost all the patients were 326 migrants from Bolivia. Race and genetics seem to be significant in drug ARs and 327 even some HLA alleles have been proposed to be associated to BNZ related 328 
 ARs.19,28 Moreover, their migrant status may determine their social support and 329 health access during treatment compared to different locations.  330  331 It is estimated that over one million people are affected with cardiac Chagas 332 disease worldwide and based on the latest studies mortality in 5 years despite 333 treatment could reach 17-18%.8,29 These results underline the urgent need of long-334 term studies with strong clinical outcomes to understand treatment’s efficacy as a 335 secondary prevention or therapeutic treatment. It is also critical to optimise 336 treatment with BNZ considering it will still be part of the treatment in the near 337 foreseeable future. Combined drug therapy or different dosages need to be 338 evaluated to achieve the maximum efficacy with the minimum of toxicity.30 At the 339 moment we have reached a point where there is no effective treatment for the 340 advanced Chagas disease and the antiparasitic drug toxicity is intolerably high as a 341 potential secondary preventive treatment in chronically infected patients.  342 343 
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 TABLES 447  448 
Table 1: Baseline demographic and clinical characteristics of patients treated 449 
with benznidazole (N=99) 450  451 Variable N (%) 
Agea 36 (9.0) 
Sex     Female 73 (73.7) 
Height (cm)a 157.0 (12) 
Weight (kg)a 66.0 (20.0) 
Country of origin    Bolivia 97 (98.0)   Paraguay 1 (1.0)   El Salvador 1 (1.0) 
Non smokers 91 (91.9) 
Alcohol intake (Grams per day)    0 65 (65.7)   0.1-4.9 18 (18.2)   5-14.9 7 (7.1)   >15 4 (4.0) 
Other medicationb 27 (27.3) 
Chagas disease form    Indeterminate 93 (93.9)   Cardiac (mild) 6 (6.1) aMedian and IQR  452 bOther medication: 12 hormonal contraception, five proton pump inhibitors, three 453 non-steroidal anti-inflammatory drugs, two Paracetamol, two antihypertensive 454 drugs, two statins and one oral antidiabetic medication 455  456 
 Table 2: Clinical characteristics and outcome of patients who did not complete treatment due to unexpected ARs, poorly 
controlled ARs or severe ARs 
 
Medical history Clinical description Main reason 
for 
suspension 
Severity 
of AR 
Date 
onset 
Day of 
suspension 
Outcome 
Female, 35, Bolivia. H. Pylori treated in the past, eosinophilia with negative parasite studies, long history of infertility 
Positive pregnancy test Withdrawal criteria Severe 52 52 Treated with BNZ for 52 days and Mequitazine for 2 days due to mild rash until positive pregnancy test. Diagnosed with ectopic tubal pregnancy. Salpingectomy and medical treatment with Metotrexate needed. Complete recovery 60 days after treatment suspension Female, 35, Bolivia, neurocysticercosis treated 2 years prior research study (no symptoms with no treatment for 2 years) 
Right side hemiparesis, initially temporary episodes and finally permanent Withdrawal criteria Severe 11 15 Treatment suspension when symptoms were reported. Hospitalisation for 5 days, treated with high doses of Dexametasone and Levetiracetam. Craneal MRI showed vascular oedema around one out of the three known lesions. Full recovery with no sequela in 18 days.  Female, 35, Bolivia, no PMH Fever, angioedema, generalised pruritic maculo-papular rash, elevated liver enzimes, neutropenia, eosinophilia, thrombocytopenia  
DRESS syndrome Severe 21 22 High doses of steroids and hospitalisation needed for 5 days. Full recovery including blood test normalisation in 55 days 
Female, 33, Bolivia, past history of anxiety Maculo-papular rash, pyrosis, sleepiness and panick attacks Anxiety Severe 12 12 Treated with Diazepam, Clorazepate and Alprazolam. Enough recovery to contiune everyday activities in 281 days 
 Female, 34, Bolivia, no PMH, no known previous history of anxiety  
Moderate insomnia after 9 days of treatment and panic attack at day 30 which led to suspend treatment  
Anxiety Moderate 9 30 Treated with Zolpidem and Diazepam. Anxiety under control since treatment suspension, insomnia improved 2-3 weeks after treatment suspension Male, 44, El Salvador, no PMH Anxiety, insomnia, distal tremor and later on persecutory delusion Anxiety Moderate 1 18 Treated with Lorazepam long-term. Assessed by Psychiatry it was diagnosed with anxiety and possible depression. Unemployment and relationship problems recognised afterwards. Female, 48, Bolivia, rosacea on treatment with Doxycycline, two previous episodes of pneumonia (17 and 4 years ago) 
Low grade fever, angioedema (periorbital and lips), hand and feet oedema, urticaria in trunk and limbs, dry coughing, mild bronchiespasm and bibasal lung infiltration (previously not known), joint pain 
Skin and pulmonary reaction Moderate 19 19 Treated with Prednisone 40mg/day, Mequitazine and Salbutamol. Full symptoms recovery in 12 days.  Reviewed by respiratory and autoimmune specialist. Complete resolution of the lung disease with no other explanation. Posterior studies found a possible scleromyositis with no link with lung symptoms Female, 37, Bolivia, no PMH Angioedema, generalised pruritic maculo-papular rash Skin Moderate 11 11 Treated with IV Metilprednisolona 40mg and IV Dexchlopherinamine 5mg followed by oral Prednisone 30mg and Mequitazine. Full recovery in 5 days PMH: previous medical history  
 Table 3: Distribution and description of ARs among patients who had ARs during treatment with  (N=85)  
AR type AR per person, N(%)a Frequency, 
N(%)b 
Severity, N(%)a Medication 
needed, 
N(%)c 
Time to onset 
(days), 
median (IQR) 
Dose to onset 
(mg), median 
(IQR) 
ARs duration 
(days), 
median (IQR) 
  1 2 >=3   Mild 
Moderate-
Severe         
General 22(81) 5(19) 0(0) 32(10) 29(91) 3(9) 4(13) 12(22) 3575(5250) 15(23) 
   Asthenia 16(100) 0(0) 0(0) 16(50) 15(94) 1(6) 0(0) 8(28) 1675(6575) 15(30) 
   Adenopathy 5(100) 0(0) 0(0) 5(16) 4(80) 1(20) 3(60) 16(11) 4050(3700) 24(27) 
   Hyporexia 4(100) 0(0) 0(0) 4(13) 4(100) 0(0) 0(0) 36(34) 10700(14225) 34(22) 
   Fever (high & low grade) 4(100) 0(0) 0(0) 4(13) 3(75) 1(25) 1(25) 16(6) 3575(1375) 4(5) 
   Othersd 3(100) 0(0) 0(0) 3 (9) 1(100) 0(0) 0(0) NA NA NA 
Digestive 25(74) 7(21) 2(6) 45(15) 45(100) 0(0) 22(49) 15(19) 3750(4850) 12(12) 
   Sickness & vomiting 18(100) 0(0) 0(0) 18(40) 18(100) 0(0) 4(22) 15(27) 3750(9100) 9(10) 
   Gastric pain 13(100) 0(0) 0(0) 13(29) 18(100) 0(0) 8(62) 21(16) 4750(4650) 9(11) 
   GERD & pyrosis 6(86) 1(14) 0(0) 8(18) 8(100) 0(0) 6(75) 12(19) 3475(5475) 16(6) 
   Dyspepsia 6(100) 0(0) 0(0) 6(13) 6(100) 0(0) 4(67) 16(45) 3775(4800) 26(52) 
Skin disorders 23(37) 30(48) 10(16) 118(39) 101(86) 17(14) 102(86) 14(17) 3800(6100) 10(11) 
   Rash 51(94) 3(6) 0(0) 57(48) 49(86) 8(14) 50(88) 12(15) 3450(5550) 9(10) 
   Pruritus 46(96) 2(4) 0(0) 50(42) 45(90) 5(10) 44(50) 13(16) 3800(5400) 11(12) 
   Otherse 11(100) 0(0) 0(0) 11(9) 7(63) 4(36) 8(73) NA NA NA 
Musculoskeletal 18(100) 0(0) 0(0) 18(6) 15(83) 3(17) 8(44) 27(35) 6550(11900) 13(14) 
   Joint & muscle pain 12(100) 0(0) 0(0) 12(67) 12(100) 0(0) 2(17) 11(26) 3150(9425) 11(15) 
   Arthritis 6(100) 0(0) 0(0) 6(33) 3(50) 3(50) 6(100) 33(23) 9300(5750) 19(13) 
Neuropsychiatric 29(57) 14(27) 8(16) 86(28) 77(90) 9(10) 31(36) 13(24) 3300(7250) 14(26) 
   Headache 33(83) 5(13) 2(5) 50(58) 47(94) 3(6) 23(46) 11(20) 3075(6550) 1(12) 
           
            
   Sleeping disorders 18(100) 0(0) 0(0) 18(21) 16(89) 2(11) 3(17) 9(28) 2425(9200) 20(32) 
   Peripheral neurology 11(100) 0(0) 0(0) 11(13) 11(100) 0(0) 1(9) 34(28) 12000(10750) 31(44) 
   Anxiety 4(100) 0(0) 0(0) 4(5) 1(25) 3(75) 3(75) 14(27) 3450(9350) 157(270) 
   Othersf 3(100) 0(0) 0(0) 3() 2(66) 1(33) 1(33) NA NA NA 
Reproductive  4(100) 0(0) 0(0) 4(1) 4(100) 0(0) 0(0) 15(24) 5000(8650) 96(63) 
Respiratory 0(0) 1(100) 0(0) 2(1) 2(100) 0(0) 2(100) 19(0) 4650(0) 12(0) 
a Row percentages. bColumn percentages . cPercentage= total frequency/medication needed NA: non-applicable if different categories are collapsed dOther general ARs: one general malaise (mild), one dry eyes (mild), one dizziness (mild) eOther skin disorders: three cases of angioedema (one mild, two moderates), one DRESS (severe), three skin peeling (mild), two skin plaques or thickening (mild), one chronic hyperpigmentation (mild), one distal swelling in ankles (moderate) fOther neuropsychiatric ARs:  two cases of emotional lability (one mild, one moderate), one case of persecutory delusion (mild) 
    
  
 
Table 4: Distribution of the 119 significant blood test disorders during 
treatment with BENZNIDAZOLE (N=98)   Blood test disorder N (%) Severity     Mild Moderate Severe Liver function test 16 (16) 11 (69) 3 (19) 2 (12) Haemoglobin 4(4) 4 (100) 0 (0) 0 (0) WBC 48 (49) 28 (58) 18 (38) 2 (4) Lymphopenia 37 (38) 19 (51) 16 (43) 2 (5) Neutropenia 14 (14) 10 (71) 3 (21) 1 (7)  Liver function test (GOT, GPT): mild 60-100 U/l, moderate 101-200 U/l, severe >201 U/l. Haemoglobin: mild 95-105 g/l, moderate 80-94g/l, severe <79 g/l. White Blood Cells (WBC): mild 3-3.9x103/µL, moderate 2-2.9x103/µL, severe <1.9x103/µL. Lymphocytes and neutrophils: mild 1.5-1.9 x103/µL, moderate 1-1.4 x103/µL, severe <0.9 x103/µL.      
 
 Table 5: AR incidence by type and incidence rate ratio (IRR) in fortnightly 
periods Type of AR Overall and time period (days)a Incidence rate (95%CI)b IRR (95%CI)c p-value TOTAL Overall 9.2(8.2-10.3)    1-15 16.8(14.4-19.6) 4.67 (3.07-7.09) <0.0001  16-30 8.0(6.2-10.1) 2.19 (1.39-3.44)   31-45 4.1(2.8-5.7) 1.16 (0.69-1.94)   46-60 4.3(2.8-6.3) 1  General Overall 1.0(0.7-1.4)    1-15 2.0(1.2-3.0) 7.35 (1.71-31.61) 0.0020   16-30 0.9(0.4-1.8) 3.35 (0.71-15.78)    31-45 0.2(0.0-0.9) 0.92 (0.13-6.51)     46-60 0.3(0.0-1.2) 1   Digestive Overall 1.4(1.0-1.8)    1-15 2.5(1.6-3.7) 4.75 (1.65-13.71) 0.0005  16-30 1.3(0.6-2.2) 2.34 (0.74-7.35)   31-45 0.2(0.0-0.9) 0.46 (0.08-2.51)   46-60 0.7(0.2-1.7) 1  Skin Overall 3.6(2.9-4.3)    1-15 6.5(5.0-8.3) 4.81 (2.46-9.39) <0.0001   16-30 3.3(2.2-4.8) 2.42 (1.18-4.97)     31-45 1.5(0.8-2.6) 1.10 (0.48-2.55)     46-60 1.6(0.8-3.0) 1   Musculoskeletal Overall 0.5(0.3-0.9)    1-15 0.7(0.3-1.5) 2.69 (0.56-12.97) 0.3005  16-30 0.2(0.0-0.8) 0.84 (0.12-5.97)   31-45 0.7(0.3-1.6) 2.76 (0.56-13.68)   46-60 0.3(0.0-1.2) 1  Neuropsychiatric Overall 2.6(2.1-3.2)    1-15 5.0(3.7-6.7) 4.50 (2.12-9.56) <0.0001   16-30 1.9(1.1-3.1) 1.69 (0.73-3.94)     31-45 1.2(0.6-2.3) 1.14 (0.45-2.88)     46-60 1.3(0.6-2.6) 1   a Number of participants on treatment on each period: 1-15=99, 16-30=92, 31-45=84, 46-60=77.  bIncidence rate: ten person-fortnights. Exact Poisson 95% CI. cMultilevel Poisson Regression adjusted by age and sex, 352 observations.   
 
 
 
 
 
 
 
  
FIGURES  
Figure 1: Kaplan-Meyer survival estimates of the time until first adverse 
reaction among patients treated with benznidazole (N=99) 
 
 
 
 
 Figure 2: Kaplan-Meier survival graph of the suspension of treatment among 
patients who did not complete treatment (N=26) compared to those who did 
(N=73) 
 
  
